HealthRX.com · Printable lab tracker
HFpEF on tirzepatide: lab results and daily home readings
Record the starting heart, kidney and blood pressure values, then log each lab panel at the times SUMMIT measured them and your daily home weight and blood pressure. Note which method the lab used for eGFR, because SUMMIT found creatinine and cystatin C can disagree while weight is falling.
Starting values
Ejection fraction and date of the echocardiogram
NT-proBNP, and troponin if measured
eGFR and methodcreatinine, cystatin C or both
Potassium and urine albumin-to-creatinine ratio
Weight, and blood pressure sitting and standing
Diuretic name and dose, and other heart-failure medicines
Lab panels
SUMMIT checked these at 12, 24 and 52 weeks; your team may choose other times.
| Date | Weeks on tirzepatide | Dose (mg) | NT-proBNP | eGFR and method | Potassium | Urine albumin-to-creatinine | Diuretic dose |
|---|---|---|---|---|---|---|---|
Daily home readings
| Date | Morning weight | BP sitting | BP standing | Pulse | Swelling or breathlessness | Vomiting or diarrhea |
|---|---|---|---|---|---|---|
What SUMMIT and the Zepbound label report
- In SUMMIT, eGFR by cystatin C dipped slightly at 12 weeks (-0.6 versus 0.5 on placebo) and was higher by 52 weeks (2.6 versus -0.3). With creatinine-based formulas the 12-week drop was significant, then reversed.[1]
- Relative to placebo, NT-proBNP was 9.7% to 10.8% lower on tirzepatide across the three time points (estimated treatment difference); the difference was significant at 12 weeks but not at 24 or 52 weeks.[1]
- Systolic blood pressure fell 4.7 to 6.4 mm Hg more than on placebo across 12 to 52 weeks.[1]
- The Zepbound label asks for kidney function checks when side effects could cause fluid loss, especially when starting or increasing the dose.[2]
- In the Zepbound weight trials, low blood pressure was reported in 1.6% versus 0.1% on placebo, and resting heart rate rose by 1 to 3 beats per minute on average.[2]
Call the same day
- Nausea, vomiting or diarrhea that does not go away: tell your healthcare provider right away. Fluid loss can cause kidney problems.[2]
- Severe stomach pain that will not go away, with or without nausea or vomiting: stop Zepbound and call your healthcare provider right away.[2]
For the cardiology or heart-failure team
- Does my lab report eGFR from creatinine, cystatin C or both, and which should we follow?
- What change in NT-proBNP or eGFR would make you act?
- How much weight change in a few days should I report?
- When will my diuretic dose be reviewed as my weight falls?
- Who do I call if vomiting or diarrhea starts?
Sources for the facts on this sheet
- Borlaug BA, Zile MR, Kramer CM, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med 2025. PMID 39551891. https://pubmed.ncbi.nlm.nih.gov/39551891/
- Eli Lilly and Company, via DailyMed. Zepbound (tirzepatide) injection, for subcutaneous use: prescribing information and Medication Guide. Effective 2026-08-28. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.